Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. The transcript discusses growth in volumes, acquisitions, and expansion of clinics. Specifically, they mention opening more than 100 pediatric clinics across their footprint within a few years. But is that about the size of individual engagements? They talk about growth efforts, acquisitions, and de novo development. They mention that acquisitions haven't been a major part of activity so far this year, but could play a role. They also mention the Brave Care investment and plans to open clinics. However, the question is about whether the individual size of what they land is growing versus their own past. They talk about expanding practices, adding practices, and enhancing hospital relationships. But do they explicitly say that each new engagement is bigger? They mention that they are building momentum, and that volumes exceed pre-COVID levels. But that's about overall volume, not unit size. They also mention that they expect adjusted EBITDA to exceed $270 million next year, but that's financial guidance. The key is whether management conveys that the deals, contracts, projects, etc., are individually larger. They talk about opening more than 100 pediatric clinics, but that's a plan, not something already signed. They also mention that they are in discussions with existing platforms for acquisitions. But they don't say that these are larger than past acquisitions. They don't compare the size of new contracts to old ones. They talk about growth in NICU days, volumes, etc., but that's volume growth, not necessarily larger unit size per engagement. The question specifically asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" I don't see any such statement. They talk about expanding practices, but that might be adding more practices, not making each practice larger. They talk about the Brave Care investment and opening clinics, but that's a new venture, not necessarily the same offering as before.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.